Back to Search Start Over

O-9 5-FU/LV + cetuximab + vemurafenib as maintenance therapy for BRAF-mutant (BRAFmut) metastatic colorectal cancer: Efficacy, safety, and exploratory biomarker findings from Cohort 1 of the MODUL trial.

Authors :
Ducreux, M.
Tabernero, J.
Grothey, A.
Arnold, D.
O'Dwyer, P.
Perdicchio, M.
Assaf, Z.
Das Thakur, M.
Irahara, N.
Tahiri, A.
Schmoll, H.
Van Cutsem, E.
de Gramont, A.
Source :
Annals of Oncology. 2021 Supplement 3, Vol. 32, pS221-S222. 2p.
Publication Year :
2021

Subjects

Subjects :
*CETUXIMAB
*BRAF genes
*COLORECTAL cancer

Details

Language :
English
ISSN :
09237534
Volume :
32
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
152686553
Full Text :
https://doi.org/10.1016/j.annonc.2021.05.013
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details